Assessment of ethnic variation in serum levels of total, complexed and free prostate specific antigen. Comparison of Maori, Pacific Island and New Zealand European populations

Brawer, 1998, Measurement of complexed PSA improves specificity for early detection of prostate cancer, Urology, 52, 372, 10.1016/S0090-4295(98)00241-6 Oesterling, 1995, Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios, J Urol, 154, 1090, 10.1016/S0022-5347(01)66984-2 Saw, 2000, Age-related reference intervals for free and total prostate-specific antigen in a Singaporean population, Pathology, 32, 245, 10.1080/pat.32.4.245.249 Smith, 1998, Use of lower prostate specific antigen cutoffs for prostate cancer screening on black and white men, J Urol, 160, 1732, 10.1016/S0022-5347(01)62395-4 Henderson, 1997, Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer, J Natl Cancer Inst, 89, 134, 10.1093/jnci/89.2.134 Vashi, 1997, Percent free prostate-specific antigen: Entering a new era in the detection of prostate cancer, Mayo Clin Proc, 72, 337, 10.4065/72.4.337 Kao, 1997, Age-related free PSA, total PSA and free PSA/total PSA ratios: establishment of reference ranges in Chinese males, Anticancer Res, 17, 1361 Cooney, 2001, Age-specific distribution of serum prostate-specific antigen in a community-based study of African-American men, Urology, 57, 91, 10.1016/S0090-4295(00)00873-6 Anderson, 1995, Age-specific reference ranges for serum prostate-specific antigen, Urology, 46, 54, 10.1016/S0090-4295(99)80158-7 Barry, 1992, The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association, J Urol, 148, 1549, 10.1016/S0022-5347(17)36966-5 Lodding, 1998, Characteristics of screening detected prostate cancer in Men 50 to 66 years old with 3 to 4ng/mL Prostate Specific Antigen, J Urol, 159, 899, 10.1016/S0022-5347(01)63766-2 Crawford, 1996, Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program, Urology, 47, 863, 10.1016/S0090-4295(96)00061-1 Bangma, 1995, The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men, Urology, 46, 773, 10.1016/S0090-4295(99)80342-2 DeAntoni, 1996, Age and race-specific reference ranges for prostate-specific antigen from a large community based study, Urology, 48, 234, 10.1016/S0090-4295(96)00091-X Catalona, 2000, Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial, Urology, 55, 372, 10.1016/S0090-4295(99)00547-6 Gelmann, 2001, PLCO Screening Trial Investigators. Relationship of demographic and clinical factors to free and total prostate-specific antigen, Urology, 58, 561, 10.1016/S0090-4295(01)01305-X Statistics New Zealand: Census Tatauranga. 2001 Census. [data online]. Available from: URL: http://www.stats.govt.nz/; 2002. Moore, 2000, Diabetes in New Zealand, Diabetes Res Clin Pract, 50, S65, 10.1016/S0168-8227(00)00181-9 New Zealand Health Information Service. Prostatectomy operations performed in publicly funded hospitals between 1997–1999. [Unpublished data. 2002.] Nacey, 1995, Analysis of the prevalence of voiding symptoms in Maori, Pacific Island and Caucasian New Zealand men, Urology, 46, 506, 10.1016/S0090-4295(99)80263-5 Malcolm, 1996, Inequities in access to and utilisation of primary medical care services for Maori and low income New Zealanders, NZ Med J, 109, 356 Davis, 1997, Patterns of general practitioner usage among Pacific people: indicative results from the Waikato Medical Care Survey 1991–2, NZ Med J, 110, 335 Sporle, 1999, Impact of changes in the death registration process upon Maori mortality statistics, NZ Med J, 112, 411 Sporle, 2002, Social class mortality differences in Maori and non-Maori men aged 15–64 during the last two decades, NZ Med J, 115, 127